Calypso, Varian combine cancer tech:
This article was originally published in Clinica
Tumour detection specialist Calypso Medical has announced plans to combine its Calypso 4D Localization System with Varian Medical Systems' treatment planning system and linear accelerators to enhance radiotherapy treatment. The 4D system, which Calypso (Seattle, Washington) claims is the first device to use a non-ionizing approach for target localisation in treatment setup and monitoring during radiation therapy delivery, aims to give clinicians improved patient positioning, motion management and tumour targeting when integrated with Varian's Eclipse and On Board Imager technologies. Integration of the 4D system and Eclipse is expected to begin after the 4D's launch - it received FDA 510(k) clearance for use in prostate therapy only in July 2006.
You may also be interested in...
FDA action awaits Sun’s manufacturing facility in Halol after it failed to adequately address GMP deviations, though India’s top-ranked drug firm appears to have effectively lowered its dependence on the site that has had a patchy compliance run.
In a surprise to the market, Dr Reddy’s and Hikma have prevailed in challenging six method-of-use patents shielding Amarin’s Vascepa in the US, opening the door for a potential at-risk launch that would likely be challenged by the originator.
Duo will study up to four novel preclinical targets identified by Sitryx that may lead to potential new drugs for autoimmune diseases, which Lilly would then commercialize.